4//SEC Filing
Belsky Marc 4
Accession 0001209191-23-043421
CIK 0001645666other
Filed
Jul 25, 8:00 PM ET
Accepted
Jul 26, 4:55 PM ET
Size
30.5 KB
Accession
0001209191-23-043421
Insider Transaction Report
Form 4
Belsky Marc
Chief Financial Officer
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−60,000→ 0 totalExercise: $22.85Exp: 2029-01-05→ Common Stock (60,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+60,000→ 60,000 totalExercise: $2.28Exp: 2029-01-05→ Common Stock (60,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+60,000→ 60,000 totalExercise: $2.28Exp: 2029-09-05→ Common Stock (60,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+220,000→ 220,000 totalExercise: $2.28Exp: 2031-01-07→ Common Stock (220,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−195,000→ 0 totalExercise: $6.84Exp: 2033-01-07→ Common Stock (195,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−60,000→ 0 totalExercise: $3.38Exp: 2029-09-05→ Common Stock (60,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−90,000→ 0 totalExercise: $3.29Exp: 2030-01-11→ Common Stock (90,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−220,000→ 0 totalExercise: $5.45Exp: 2031-01-07→ Common Stock (220,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+90,000→ 90,000 totalExercise: $2.28Exp: 2030-01-11→ Common Stock (90,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2023-07-24−140,000→ 0 totalExercise: $14.55Exp: 2032-01-04→ Common Stock (140,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+140,000→ 140,000 totalExercise: $2.28Exp: 2032-01-04→ Common Stock (140,000 underlying) - Award
Employee Stock Option (right to buy)
2023-07-24+195,000→ 195,000 totalExercise: $2.28Exp: 2033-01-07→ Common Stock (195,000 underlying)
Footnotes (6)
- [F1]Fully vested and exercisable.
- [F2]On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
- [F3]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2020, subject to the Reporting Person continuing to provide service through each such date.
- [F4]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
- [F5]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date.
- [F6]One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.
Documents
Issuer
Kezar Life Sciences, Inc.
CIK 0001645666
Entity typeother
Related Parties
1- filerCIK 0001382629
Filing Metadata
- Form type
- 4
- Filed
- Jul 25, 8:00 PM ET
- Accepted
- Jul 26, 4:55 PM ET
- Size
- 30.5 KB